Diligence memo · auto-generated · as of July 2, 2026
Scipher Medicine Corp
Scipher Medicine Corp looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Scipher Medicine Corp operates in Biotechnology, based in WALTHAM.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Scipher Medicine Corp has raised $123M in disclosed capital across 7 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $82M on 2021-03-12.
Most recent recorded round closed around 2024-05-02.
Valuation (modeled)modeled
Provath models Scipher Medicine Corp at approximately $56M (range $18M–$86M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.11× the median modeled value of Series C Biotechnology companies in 2022–2024 (111 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 13 months.
Last raise 2.2 yr ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
The last round was 14.0× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 92% of Biotechnology peers (4293 compared).
Modeled value ranks above 48% of those peers.
Closest niche peers: Dianthus Therapeutics, Inc., Satellite Biosciences, Inc., Deepcell, Inc., Ventus Therapeutics U.S., Inc., Morphic Holding, Inc..
Peoplefiled
17 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.